1] Institute for Clinical Evaluative Sciences, Toronto, Ontario, Canada [2] Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada.
1] Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada [2] Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario, Canada.
Am J Gastroenterol. 2014 Nov;109(11):1698-704. doi: 10.1038/ajg.2014.78. Epub 2014 Jul 8.
The sessile serrated adenoma/polyp (SSA/P) is increasingly recognized as an important precursor to colorectal cancer (CRC) and may contribute to proximal postcolonoscopy CRCs. Hyperplastic polyps (HPs) generally follow a more benign course than do SSA/Ps, but they have a similar histologic appearance. Our aims were to identify patient and polyp factors associated with reclassification of HPs as SSA/Ps during a central pathology review and to characterize and compare their subsequent clinical management with other polyps.
From 2003 to 2008, we prospectively enrolled asymptomatic persons aged 50-74 years in a study of screening colonoscopy. Because criteria for SSA/P diagnosis evolved over our study period, we initiated a second review of all HPs >5 mm in size in 2011, with reclassification of polyps if indicated. Rates of subsequent colonoscopies, polypectomies, and CRCs were identified.
We enrolled 2,527 persons who underwent colonoscopy in whom 111 had HPs >5 mm. Thirty-two of the 111 participants (28.8%) with HPs >5 mm had their polyps reclassified as SSA/Ps. There were no significant differences in patient characteristics between those with reclassified SSA/Ps and those who had HPs >5 mm. SSA/Ps were more likely to be proximal (P<0.001) and larger (P<0.007) than the HPs. In all, 48.3% of those with high-risk adenomas received appropriate follow-up compared with 26.1% of those with high-risk SSA/Ps.
Almost 1/3 of recently diagnosed HPs >5 mm were reclassified as SSA/Ps. Patients previously diagnosed with larger HPs in the proximal colon may benefit from a pathologic review to ensure appropriate diagnosis and follow-up.
无蒂锯齿状腺瘤/息肉(SSA/P)越来越被认为是结直肠癌(CRC)的重要前体,并且可能导致结肠镜检查后的近端 CRC。增生性息肉(HPs)的病程通常比 SSA/Ps 更良性,但它们具有相似的组织学外观。我们的目的是确定与在中央病理审查期间将 HPs 重新分类为 SSA/Ps 相关的患者和息肉因素,并对其与其他息肉的后续临床管理进行特征描述和比较。
我们在 2003 年至 2008 年期间前瞻性地招募了年龄在 50-74 岁之间的无症状者进行筛查结肠镜检查。由于 SSA/P 诊断标准在我们的研究期间发生了变化,因此我们于 2011 年启动了对所有>5mm 的 HPs 的第二次审查,如果有指征则重新分类息肉。确定了后续结肠镜检查、息肉切除术和 CRC 的发生率。
我们共招募了 2527 名接受结肠镜检查的患者,其中 111 名患者的 HPs>5mm。在 111 名 HPs>5mm 的患者中,有 32 名(28.8%)患者的息肉被重新分类为 SSA/Ps。重新分类为 SSA/Ps 的患者与 HPs>5mm 的患者之间在患者特征方面没有显著差异。SSA/Ps 更有可能位于近端(P<0.001)且更大(P<0.007)。所有高危腺瘤患者中,有 48.3%接受了适当的随访,而高危 SSA/Ps 患者中仅有 26.1%接受了适当的随访。
最近诊断的>5mm 的 HPs 中,近 1/3 被重新分类为 SSA/Ps。以前在近端结肠中诊断出较大 HPs 的患者可能需要进行病理复查,以确保正确的诊断和随访。